NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Sobieraj DM, Baker WL, Weeda ER, et al. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Mar. (Comparative Effectiveness Reviews, No. 194.)
Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma [Internet].
Show detailsTable ADrugs included in the review
| Class | Drugs |
|---|---|
| ICS | Beclomethasone,a budesonide,a ciclesonide,a Flunisolide,a fluticasone,a mometasone,a triamcinoloneb |
| LABA | Arformoterol, formoterol,a olodaterol, salmeterol,a vilanterol,a,c |
| LAMA | Aclidinium, glycopyrrolate, tiotropium,a umeclidinium |
FDA = Food and Drug Administration; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist
- a
Currently with FDA approval for asthma, either as a single ingredient product or as a component of a multi-ingredient product.
- b
Previously FDA approved, although discontinued in 2010.
- c
Considered an ultra-long-acting β2-agonist.
- Table A, Drugs included in the review - Intermittent Inhaled Corticosteroids and...Table A, Drugs included in the review - Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma
Your browsing activity is empty.
Activity recording is turned off.
See more...